A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma
A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma
复制标题
DOI：
10.1046/j.1365-2141.2000.02093.x
复制
发表时间：
2000-06-01
影响因子：
6.5
通讯作者：
Bataille, R
中科院分区：
文献类型：
--
作者：
Moreau, P;Harousseau, JL;Bataille, R
为了在不增加大剂量化疗毒性的前提下提高晚期多发性骨髓瘤(MM)的完全缓解率(CR率)，我们采用了一种新的预处理方案，即BE-8[一种抗白介素6(IL-6)小鼠单抗]和地塞米松联合大剂量马法兰(220 mg/m(2))和自体干细胞移植治疗16例晚期多发性骨髓瘤患者。通过C-反应蛋白定量评价IL-6活性在所有患者中都受到了强烈的抑制，这与这种联合治疗获得的高CR率有关。
To improve the complete response (CR rate in advanced multiple myeloma (MM) without increasing the toxicity of high-dose therapy we have used a new conditioning regimen, A combination of BE-8 [an anti-interleukin 6 (IL-6) murine monoclonal antibody] and dexamethasone followed by high-dose melphalan (220 mg/ m(2)) and autologous stem cell transplantation was used to treat a series of 16 patients with advanced multiple myeloma. A strong inhibition of IL-6 activity evaluated by quantification of C-reactive protein was observed in all patients and was correlated with the high CR rate achieved with this combination therapy.